Therefore, we propose to include selected CYP51A1 variants into personalized diagnostics panel for evaluating risks for pediatric cataract, neonatal hepatic failure, global developmental delay, azole susceptibility, and cardiovascular and metabolic diseases. Here, CYP51A1 is linked to Hepatic failure.